Michael L. Steinberg

Introduction: Disaster Preparedness and Emergency Management in Radiation Oncology.

Journal: Seminars in radiation oncology

Published: July 11, 2026

Navigating the Fragmented Landscape of Radiation Oncology Incident Reporting: A Framework for Regulatory Compliance, Institutional Safety, and Systemic Learning.

Journal: Seminars in radiation oncology

Published: June 10, 2026

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Journal: European urology

Published: May 11, 2026

Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 16, 2026

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.

Journal: International journal of radiation oncology, biology, physics

Published: March 09, 2026

Workforce Investments in Telehealth Suicide Prevention in Emergency Departments: Implementation Costs of a Centralized Behavioral Health Consultation Service.

Journal: The journal of behavioral health services & research

Published: March 03, 2026

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

Journal: European urology oncology

Published: January 12, 2026

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial.

Journal: JAMA network open

Published: December 17, 2025

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis.

Journal: JAMA oncology

Published: November 20, 2025

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

Journal: JNCI cancer spectrum

Published: November 17, 2025

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Introduction: Disaster Preparedness and Emergency Management in Radiation Oncology.

Introduction: Disaster Preparedness and Emergency Management in Radiation Oncology.

Navigating the Fragmented Landscape of Radiation Oncology Incident Reporting: A Framework for Regulatory Compliance, Institutional Safety, and Systemic Learning.

Navigating the Fragmented Landscape of Radiation Oncology Incident Reporting: A Framework for Regulatory Compliance, Institutional Safety, and Systemic Learning.

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE.

Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE.

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.

Workforce Investments in Telehealth Suicide Prevention in Emergency Departments: Implementation Costs of a Centralized Behavioral Health Consultation Service.

Workforce Investments in Telehealth Suicide Prevention in Emergency Departments: Implementation Costs of a Centralized Behavioral Health Consultation Service.

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial.

Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial.

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis.

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis.

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

Concerns Regarding Follow-Up Duration and End Point Validity-Reply.

Concerns Regarding Follow-Up Duration and End Point Validity-Reply.